GAMMAGARD LIQUID ERC Is Now Available in the U.S.

GAMMAGARD LIQUID ERC (immune globulin infusion [human]) with less than or equal to 2 µg/mL IgA in a 10% solution, by prescription, is now available in the U.S. GAMMAGARD LIQUID ERC is approved as replacement therapy for people 2 years of age and older with primary immunodeficiency (PI). It is a liquid immune globulin (IG) therapy that does not require reconstitution and can be administered intravenously or subcutaneously.

GAMMAGARD LIQUID ERC shares the same manufacturing process as the other liquid formulations in the Takeda IG portfolio, and features an enhanced removal capability (ERC) to reduce the IgA content. It is available in two liquid vial sizes, 5 g/50 mL and 10 g/100 mL, and can be stored up to 24 months at room temperature (25 °C; 77 °F) or up to 36 months refrigerated (2-8 °C; 36-46 °F).

“As the latest addition to our broad IG portfolio, GAMMAGARD LIQUID ERC underscores our ongoing dedication to providing differentiated therapeutic options to meet the varied needs of people with primary immunodeficiency, including those who require an option with low IgA content,” said Uthra Sundaram, senior vice president and head of Takeda’s U.S. Plasma-Derived Therapies Business Unit. “As a ready-to-use liquid, GAMMAGARD LIQUID ERC does not require reconstitution and can be administered intravenously or subcutaneously, which may help ease the administration burden for patients and their healthcare providers.”